ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO885

Effects of Vitamin D Supplementation on Markers of Bone and Mineral Metabolism in Pediatric Patients with Early and Late CKD

Session Information

  • Mineral Disease: CKD-Bone
    November 04, 2017 | Location: Hall H, Morial Convention Center
    Abstract Time: 10:00 AM - 10:00 AM

Category: Mineral Disease

  • 1203 Mineral Disease: CKD-Bone

Authors

  • Haffner, Dieter, Hannover Medical School Children's Hospital, Hannover, Germany
  • Lerch, Christian, Hannover Medical School Children's Hospital, Hannover, Germany
  • Schaefer, Franz S., University Children’s Hospital Heidelberg, Heidelberg, Germany
  • Shroff, Rukshana, Great Ormond Street Hospital for Children, London, United Kingdom

Group or Team Name

  • ESPN CKD-MBD working group and 4C Study consortium
Background

Recent research findings suggest that vitamin D may have PTH independent effects on the regulation of bone and mineral metabolism. We investigated the effects of vitamin D supplementation on circulating fibroblast growth factor 23 (FGF23), Klotho, and sclerostin levels in two pediatric cohorts with early and late CKD.

Methods

Eighty vitamin D deficient children were selected: 40 with early CKD from the ERGO Study, a randomized placebo-controlled trial of ergocalciferol supplementation in children (mean eGFR 55 ml/min/1.73m2), and 40 with advanced CKD from the observational 4C Study (eGFR 24 ml/min/1.73m2, p<0.01). In each study 20 children received vitamin D supplementation, and 20 age and eGFR-matched children not on vitamin D served as controls. Z-scores (SDS) were calculated for serum levels of Klotho, FGF23, and sclerostin, at baseline and after a median period of 8 months.

Results

Untreated patients in the ERGO study had normal FGF23 (0.31 SDS) but decreased levels of klotho (-0.77 SDS) and sclerostin (-1.04 SDS), whereas untreated children in the 4C cohort had increased FGF23 (3.87 SDS) and sclerostin (0.76 SDS), but normal klotho (-0.27 SDS) levels. Vitamin D supplementation further increased FGF23 levels in 4C but not in ERGO patients. Serum klotho and sclerostin normalized during vitamin D supplementation in ERGO but remained unaffected in 4C patients. In the whole cohort significant differences between vitamin D treated patients and controls were noted for Klotho at eGFR 40-70 ml/min/1.73 m2 and for sclerostin at eGFR 60-70 ml/min/1.73 m2. 25-hydroxyvitamin D levels >75nMol/L was independently associated with the changes in Klotho and sclerostin levels.

Conclusion

Vitamin D supplementation normalizes Klotho and sclerostin levels in vitamin D deficient children with early CKD, but further increases FGF23 levels in vitamin D deficient children with advanced CKD.